基石藥業-B(02616.HK):在AACR年會公佈多特異性抗體候選療法CS2006/NM21-1480臨牀前研究數據
格隆匯4月13日丨基石藥業-B(02616.HK)發佈公吿,多特異性抗體CS2006/NM21-1480臨牀前研究數據已在2022年美國癌症研究協會(AACR)年會上公佈。
根據披露,藥代動力學/藥效學模型研究結果顯示,經過優化親和力的CS2006/NM21-1480可在較寬的劑量範圍內同時達到最佳的PD-L1抑制與4-1BB激活,從而有利於臨牀劑量的選擇。CS2006/NM21-1480單藥療法在冷、熱腫瘤模型中均有療效;與CD3-T細胞誘導劑聯合使用可增強抗腫瘤活性,促進腫瘤內部CD8陽性記憶T細胞形成。 此次研究數據為CS2006/NM21-1480作為潛在同類最佳下一代免疫腫瘤療法的臨牀開發提供了轉化支援。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.